Orphan drugs: Is your medical affairs team leading the fray or lagging behind?
Traditional commercial models simply don’t work for orphan drugs, not least because the physician and patient populations are so much smaller – and the value of individual relationships is consequently higher as a result. But some players are achieving success with high-performing medical affairs teams and sophisticated strategies. Getting medical affairs right has emerged as the key success factor for drugs companies gaining traction in rare diseases markets. So, what exactly are they doing? What works and why?
Medical Affairs in Orphan Drugs delves into the brave new world of rare diseases to find out what the new ‘super-breed’ of medical affairs specialists are doing to edge ahead. Eight leading experts in the US and Europe give their views on the evolving orphan drugs market and how medical affairs is adapting.
Download now – and find out how to succeed in orphan drug markets.
Ensure your medical affairs team is geared up to tackle orphan drugs. Download this report now.
All eyes are on medical affairs as more and more drug manufacturers throw their hats into the ring and enter the orphan drugs marketplace. But the tried and tested approaches that delivered results in traditional markets are not right in this new arena. Reinvention is the key, and medical affairs teams need to prepare their strategies with care and precision. Only a handful of highly influential physicians combined with a tiny patient population means there’s no room for trial and error. Get it right and the rewards are there. Get it wrong and it’s impossible to hide in the smaller and rather more personal world of rare diseases…
Find out how to adapt your medical affairs strategy for orphan drugs. Download this report now.
The eight influencers interviewed for this report are senior medical affairs and rare diseases experts based in the US and Europe. All have shared their views and perspectives on this growth area; some are identified and some have chosen to remain anonymous.
“The role of medical affairs is even more critical and more deep than in these larger indications. Part of it is that you're basically dealing with a disease that might affect a couple of hundred or 1000 patients across the globe. That means you have maybe a dozen of real experts in that field, so there is a much more individual collaboration with these world-class expert centres in a given disease that we need to engage with. It's a much closer relationship in the sense that we continue to support the research in these centres; we continue to support medical education and we continue to support disease awareness, which is very critical.”
Hartmann Wellhoefer
“I think a really important thing is the cultivation of creative ways to continuously generate data. The key challenge with an orphan condition is you have a small population. For any drug that comes out, there's lots of questions outstanding - even when it's approved - on long-term safety, real world safety, real world efficacy, efficacy in subpopulations, efficacy in combination with other drugs, efficacy looking at more of these real world endpoints that may or may not have been included in your pivotal trial.”
Vice President, Head of Medical Affairs, Biotechnology Company
“[You need to] get people with the right level of skills. You need to have people who can learn quickly where technical expertise is concerned but who are excellent communicators, who are having a good level of soft skills and the mental flexibility to deal with the fast pacing change in our industry. To attract and retain and develop those people will be the key challenge for medical affairs but not just medical affairs in the industry.”
Michael Zaiac
Hear more from the experts – order today.
Order now and get a head-start on your target orphan drugs markets.
This critical intelligence is available for immediate download — order your copy now
Need more information? Contact a consultant for an executive summary and sample pages from the report.
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved